Randomised Clinical Trial of Ifosfamide, Carboplatin and Etoposide with Mid-Cycle Vincristine (VICE) versus Standard Practice Chemotherapy in Patients with Limited Small-Cell Lung Cancer (SCLC) and Good Performance Status.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antineoplastics; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Ifosfamide; Vincristine
Indications Small cell lung cancer
Focus Therapeutic Use

Most Recent Events

19 Dec 2013 Biomarkers information updated
22 Apr 2009 Additional lead trial centre (Medical Research Council) and investigator (Nick Thatcher) identified as reported by United Kingdom Clinical Research Network.
14 Apr 2009 New source identified and integrated (United Kingdom Clinical Research Network).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight